Podcast Summary: “Google For Doctors”: How the G20 and World Bank Can Help Tackle Antibiotic Resistance – Lord Jim O’Neill

The CGD Podcast, Center for Global Development / June 14, 2016
Host: Rajesh Merchandani
Guest: Lord Jim O’Neill (Economist, Author of UK Government AMR Review)

Overview

This episode tackles the global threat of antimicrobial resistance (AMR), focusing on the findings and recommendations from Lord Jim O’Neill’s landmark UK government review. O’Neill discusses why AMR is not only a health crisis but also a profound economic and development challenge. The conversation explores why the world needs urgent action, the vital roles of the G20 and multilateral banks like the World Bank, and why incentives for new drugs, diagnostics, and widespread public awareness are crucial.

Key Discussion Points

The Dire Threat of AMR

• Staggering Projections

  • By 2050, unchecked AMR could cause 10 million deaths annually and cost the world $100 trillion in lost economic output.
    • Quote: “By 2050, the 10 million deaths a year that we suggest could happen, that would translate into somebody dying every three seconds. Pretty scary.”
      (Lord O’Neill, 02:41)

• The Real-World Impact

  • AMR is already leading to high death tolls, especially compared to recent pandemic threats.
  • Margaret Chan’s warning: Surgeons could refuse to operate due to infection risks with no effective antibiotics; the drug pipeline is “empty.”
    • Quote: “We will see more deaths from AMR than cancer... Surgeons would refuse to do any transplant.”
      (Dr. Margaret Chan, 01:09)

AMR as a Market Failure – The Economic Dimension

• Why It’s a "Market Failure"
  • Developing new antibiotics isn’t profitable for pharmaceutical companies; market incentives push them to maximize sales, but widespread use accelerates resistance.
  • No company, individual, or country bears the cost of resistance, leading to collective inaction.
    • Quote: “It does not pay pharmaceutical companies to develop new antibiotics… all the market incentives... are to produce something and sell a lot of it.”
      (George Osborne, 03:44)
    • O’Neill’s comment: “It's a classic market failure... Those associated with production and commercialization aren’t incentivized to worry about these negative externalities.”
      (05:54)

Main Recommendations from the O’Neill Review

• Three Pillars:
  1. Reducing Demand for Antibiotics
  2. Increasing Supply (New Drugs & Diagnostics)
  3. Improving Global Cooperation

1. Reducing the Demand for Antibiotics

• Cultural Overuse

  • Societies treat antibiotics “like candy” (or “sweets”, UK).
  • Most are unaware of the personal and societal damage from improper use.
    • Quote: “We need to stop treating these things like candy, or as we'd say in the UK, like sweets.”
      (O’Neill, 06:45)

• Mass Global Awareness Campaign

  • Similar to anti-smoking or HIV/AIDS campaigns.
  • Needs to be culturally tailored (e.g., use of local social media platforms like WeChat in China, Bollywood in India, British football globally).
    • Quote: “Some major awareness thing about what antibiotics actually are... is the minimum.”
      (O’Neill, 08:15)
    • Awareness success examples: HIV campaigns, breast cancer, use of sports and pop culture.
      (11:28)

2. Improving Supply: Incentivizing New Drugs and Diagnostics

• Market Entry Rewards (“Prizes”)

  • G20 should fund a “market entry reward” for innovative antibiotics—essentially a substantial prize to pharmaceutical companies for successful new drugs.
    • Quote: “We want [G20] to embrace the right mechanism, hopefully including something close to our recommended mechanism, which we call market entry rewards…”
      (O’Neill, 12:45)
    • Funding could partially come from a “pay to play” mechanism taxing pharma companies participating in the antibiotics market.

• Diagnostics: “Google for Doctors”

  • Mandate diagnostics before antibiotics prescriptions, at least in developed countries (by 2020).
  • Improved rapid tests reduce unnecessary antibiotic use, stimulating tech and venture capital interest.
    • Quote: “I like to call it Google for doctors… our doctors, our clinicians… make a really educated guess whether we need an antibiotic or not… Why don't we do something about it?”
      (O’Neill, 16:10)
  • Extend market entry/prizes to diagnostics, aiding TB and similar high-burden diseases in emerging economies.

3. Global Cooperation: The Role of the G20, UN, and World Bank

• G20 as Financiers and Conveners

  • 2016’s Chinese-chaired G20 seen as crucial to advance commitments for drugs and diagnostics funding.

• World Bank and Multilateral Development Banks

  • Could underwrite procurement and rollout of diagnostics in the developing world—less so for new drug R&D, more for implementation.
    • Quote: “If you take all of our interventions together, we… guess $40 billion over 10 years. If that…stop[s] the loss of $100 trillion worth of global GDP, that's… a two and a half thousand percent return.”
      (O’Neill, 19:38)
  • AMR should be linked to sustainable development, clean water, and sanitation.

Notable Quotes & Memorable Moments

• On the Urgency of Action:

  • “We better do something about it… the number of deaths and the economic cost of not doing something actually make the financial crisis… seem like small potatoes compared to this potential risk.”
    — Lord Jim O’Neill (03:00)

• Framing the Challenge:

  • “People worry about things in the world. This is up there as something that we need to stop any chance of this happening.”
    — Lord Jim O’Neill (03:24)

• On Diagnostics & Innovation:

  • “If you want to really stimulate the market and get venture capital wanting to take this seriously… If they see evidence that policymakers are adopting that kind of approach. The VC world solves that problem for you.”
    — Lord Jim O’Neill (17:00)

• Investment Logic:

  • “To stop 10 million people in the world dying and to stop the loss of $100 trillion worth of GDP potential—that seems to me like pretty good investment.”
    — Lord Jim O’Neill (20:10)

Key Timestamps

• 00:05 — Introduction, scale of AMR problem, guest welcome (Rajesh Merchandani, Lord Jim O’Neill).
• 01:09 — Margaret Chan (WHO) on the future if AMR unchecked.
• 03:44 — George Osborne (UK Finance Minister) explains why AMR is an economics & market failure issue.
• 05:54 — O’Neill introduces the 10 recommendations.
• 06:45 — Overuse of antibiotics as a cultural problem.
• 08:15 — The need for a global, tailored awareness campaign.
• 11:28 — Mass awareness campaigns: lessons from HIV/AIDS, breast cancer.
• 12:45 — The case for G20-led “market entry rewards” for new antibiotics.
• 16:10 — Google for doctors: mandatory diagnostics before prescribing.
• 18:32 — World Bank and multilaterals underwriting diagnostics.
• 19:38 — Cost/benefit of action on AMR.
• 20:10 — Closing thoughts on the value of investing to avert catastrophe.

Conclusion

Lord Jim O’Neill urges the world to confront AMR as both a public health and economic priority. His prescription spans global awareness, tough market interventions, and commitments from the world’s major economies and development banks. Success, he argues, requires “internalizing” the costs of inaction, fostering innovation and diagnostics, and harnessing collective action to prevent an avoidable catastrophe.